---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000064"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:11:08.324602+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q3 net loss $102.6M ($1.50/share); cash $495M after public offering; pipeline advances

## Summary
- Net loss of $102.6M ($1.50/share) vs $68.9M ($1.75/share) in Q3 2022; non-GAAP adjusted net loss $98.1M ($1.44/share).
- Cash, cash equivalents and securities $495M as of Oct 5, 2023, including $242M net from public offering of 11.76M shares at $22.
- BHV-1300 IgG degrader showed >90% IgG reduction in non-human primates; IND submission on track for 2023.
- BHV-7000 Phase 1 EEG study confirmed CNS target engagement; Phase 3 focal epilepsy trial to start in 2023.
- Completed enrollment in Phase 3 study of taldefgrobep alfa in SMA; troriluzole MAA under EMA review.

## SEC filing metadata
- accession: 0001935979-23-000064
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000064/0001935979-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000064/bhvn-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000064
- JSON: https://secwatch.observer/filing/0001935979-23-000064.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.